©2024 Stanford Medicine
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness
Not Recruiting
Trial ID: NCT04427501
Purpose
The purpose of this study is to measure how well LY3819253 and LY3832479 work against the
virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early
symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much
virus is in the body at various times during the study. Participation could last about 12
weeks and includes one required visit to the study site, with the remainder of assessments
performed in the home or by phone.
Pediatric participants, with mild to moderate COVID-19 illness, will enroll in a single-arm
(Arm 22), open-label addendum to evaluate the pharmacokinetics and safety of LY3819253 and
LY3832479. Enrollment began on March 31, 2021, and completed on September 24, 2021.
Pediatric participants, with mild to moderate COVID-19 illness, will enroll in a single-arm
(Arm 23), open-label addendum to evaluate the pharmacokinetics and safety of LY3853113.
Enrollment began on August 19, 2022, and completed on February 21, 2023.
Official Title
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Stanford Investigator(s)
Andra Leah Blomkalns
Redlich Family Professor
Eligibility
Inclusion Criteria:
- Are currently not hospitalized. (Not applicable to participants in treatment arm 22.)
- Have one or more mild or moderate COVID-19 symptoms: Fever, cough, sore throat,
malaise, headache, muscle pain, gastrointestinal symptoms, or shortness of breath with
exertion. (Not applicable to participants in treatment arm 22.)
- Must have sample taken for test confirming viral infection no more than 3 days prior
to starting the drug infusion
- Are males or females, including pregnant females who agree to contraceptive
requirements
- Understand and agree to comply with planned study procedures
- Agree to the collection of nasopharyngeal swabs and venous blood. (Not applicable to
participants in treatment arms 20-21.)
- The participant or legally authorized representative give signed informed consent
and/or assent
Participants in treatment arms 7-9, 13-14, and 18-21 ONLY
- Are greater than or equal to (≥)18 years of age and must satisfy at least one of the
following at the time of screening
- Are pregnant
- Are ≥65 years of age
- Have a body mass index (BMI) ≥35
- Have chronic kidney disease (CKD)
- Have type 1 or type 2 diabetes
- Have immunosuppressive disease
- Are currently receiving immunosuppressive treatment or
- Are ≥55 years of age AND have:
- cardiovascular disease (CVD), OR
- hypertension, OR
- chronic obstructive pulmonary disease (COPD) or other chronic respiratory
disease
- Are 12-17 years of age (inclusive) AND satisfy at least one of the following at the
time of screening
- Are pregnant
- Have a body mass index (BMI) ≥85th percentile for their age and gender based on
CDC growth charts, https://www.cdc.gov/growthcharts/clinical_charts.htm
- Have sickle cell disease
- Have congenital or acquired heart disease
- Have neurodevelopmental disorders, for example, cerebral palsy
- Have a medical-related technological dependence, for example, tracheostomy,
gastrostomy, or positive pressure ventilation (not related to COVID-19)
- Have asthma or reactive airway or other chronic respiratory disease that requires
daily medication for control
- Have type 1 or type 2 diabetes
- Have chronic kidney disease
- Have immunosuppressive disease, or
- Are currently receiving immunosuppressive treatment
Participants in treatment arm 22 ONLY
- Are 0 (≥ 32 weeks gestational age AND ≥ 1.5 kilograms [kg]) to 17 years of age
(inclusive) AND satisfy at least one of the following risk factors at the time of screening
- Are pregnant
- Have a BMI ≥85th percentile for their age and gender based on CDC growth charts,
https://www.cdc.gov/growthcharts/clinical_charts.htm
- Have sickle cell disease
- Have congenital or acquired heart disease
- Have neurodevelopmental disorders, for example, cerebral palsy, autism, or Down
syndrome (FAIR Health 2020; Spreat et al. 2020)
- Have a medical-related technological dependence, for example, tracheostomy,
gastrostomy, or positive pressure ventilation (not related to COVID-19)
- Have asthma, cystic fibrosis, reactive airways disease or other chronic respiratory
disease that requires daily medication for control
- Have type 1 or type 2 diabetes
- Have chronic kidney disease
- Have immunosuppressive disease, or
- Are currently receiving immunosuppressive treatment, or
- Are less than (<) one year of age.
- Have one or more COVID-19 symptoms
- Shortness of breath/difficulty breathing
- Fever
- Sore throat
- Nausea
- Diarrhea
- Tiredness
- Headache
- New loss of taste
- Nasal congestion/runny nose
- Chills
- Stomachache
- Vomiting
- Cough
- Muscle/body aches and pain
- New loss of smell
- Poor appetite or poor feeding (in babies)
Participants in treatment arm 23 ONLY:
Must have first positive result sample of current SARS-CoV-2 viral infection ≤3 days prior
to start of treatment administration.
Participant can have COVID previously and still meet criteria for this addendum. Positive
result needs to be from a current infection.
Are 0 (≥ 38 weeks gestational age and ≥ 3.3 kg) to <12 years of age at the time of
screening, or are 12 to 17 and weighing <40 kg; and
- Have mild to moderate COVID-19 disease, including one or more COVID-19 symptoms within
the last 7 days
- Shortness of breath/difficulty breathing
- Fever
- Sore throat
- Nausea
- Diarrhea
- Tiredness
- Headache
- New loss of taste
- Nasal congestion/runny nose
- Chills
- Malaise
- Vomiting
- Cough
- Muscle/body aches and pain
- New loss of smell
- Poor appetite or poor feeding (in babies under 1 year old)
Exclusion Criteria:
- Have oxygen saturation (SpO2) less than or equal to (≤)93 percent (%) on room air at
sea level or ratio of arterial oxygen partial pressure (PaO2 in millimeters of
mercury) to fractional inspired oxygen (FiO2) less than (<)300, respiratory rate
greater than or equal to (≥)30 per minute, heart rate ≥125 per minute due to COVID-19
- Require mechanical ventilation or anticipated impending need for mechanical
ventilation due to COVID-19
- Have known allergies to any of the components used in the formulation of the
interventions
- Have hemodynamic instability requiring use of pressors within 24 hours of
randomization
- Suspected or proven serious, active bacterial, fungal, viral, or other infection
(besides COVID-19) that in the opinion of the investigator could constitute a risk
when taking intervention
- Have any co-morbidity requiring surgery within <7 days, or that is considered
life-threatening within 29 days
- Have any serious concomitant systemic disease, condition or disorder that, in the
opinion of the investigator, should preclude participation in this study
- Have a history of a positive SARS-CoV-2 test prior to the one serving as eligibility
for this study
- Have received an investigational intervention for SARS-CoV-2 prophylaxis within 30
days before dosing
- Have received treatment with a SARS-CoV-2 specific monoclonal antibody
- Have received convalescent COVID-19 plasma treatment
- Have participated in a previous SARS-CoV-2 vaccine study or have received a SARS-CoV-2
vaccine
- Have participated, within the last 30 days, in a clinical study involving an
investigational intervention. If the previous investigational intervention has a long
half-life, 5 half-lives or 30 days, whichever is longer, should have passed
- Are concurrently enrolled in any other type of medical research judged not to be
scientifically or medically compatible with this study
- Mothers who are breast feeding
Participants in Treatment Arm 22 ONLY
- Have a diagnosis of Multisystem Inflammatory Syndrome in Children (MIS-C) in the
opinion of the investigator
- Are currently hospitalized for treatment of COVID-19. Other reasons for
hospitalization are acceptable.
Participants in treatment arm 23 ONLY
- SpO2 ≤ 93% on room air at sea level, or while on chronic oxygen therapy and/or
respiratory support due to underlying non-COVID-19 related comorbidity, respiratory
rate ≥30 per minute, and heart rate ≥125 per minute due to COVID-19 (FDA February
2021)
- Require mechanical ventilation or anticipated impending need for mechanical
ventilation due to COVID-19
- Have known allergies to any of the components used in the formulation of the
interventions
- Have hemodynamic instability requiring use of pressors within 24 hours of
randomization
- Suspected or proven serious, active bacterial, fungal, viral, or other infection
(besides COVID-19) that in the opinion of the investigator could constitute a risk
when taking intervention
- Have any co-morbidity requiring surgery within 7 days, or that is considered
life-threatening within 29 days
- Have any serious concomitant systemic disease, condition or disorder that, in the
opinion of the investigator, should preclude participation in this study.
- Have received treatment with a SARS-CoV-2 specific monoclonal antibody or remdesivir
within 90 days before dosing.
- Have received convalescent COVID-19 plasma treatment within 90 days before dosing
- Have participated, within the last 30 days, in a clinical study involving an
investigational intervention. If the previous investigational intervention has a long
half-life, 5 half-lives or 30 days, whichever is longer, should have passed
- Are concurrently enrolled in any other type of medical research judged not to be
scientifically or medically compatible with this study
- Are currently pregnant or breast feeding
Intervention(s):
drug: LY3819253
drug: Placebo
drug: LY3832479
drug: LY3853113
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
833-277-0197